WFDC2 and ovarian cancer: For example, CA-125 and HE4 were shown to be the best among all two biomarker combinations in distinguishing the benign cells from early stage of ovarian cancer at 74.2 % sensitivity and 85 % specificity, whereas, CA-125, HE4, and EGFR considerably distinguish the benign from malignancy at 75.9 % sensitivity and 87.5 % specificity (Nolen et al., 2010).